Iovance Biotherapeutics, Inc.
http://www.iovance.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Iovance Biotherapeutics, Inc.
Deal Watch: Leo Pharma Adds Rare Dermatology Disorder Candidate In Timber Buyout
Plus deals involving SK Biopharmaceuticals, Hikma and Proteovant, Day One/Sprint, Eyenovia/Formosa, Clinigen/CNX, Ikena/Pionyr and more.
Finance Watch: Apogee, Sagimet Launch First Big US IPOs Of The Summer
Public Company Edition: Apogee grossed $300m and Sagimet raised $85m in the biggest initial public offerings in the US since Acelyrin’s $540m IPO in May. Also, Bausch entered into a $600m funding facility with KKR, Bicycle raised $200m in a FOPO and Caribou garnered $150m from an offering and Pfizer.
40+ Candidates Give US FDA Plenty Of Latitude While Growing 2023 Novel Approval Count From 2022
User fee goal dates in the second half of 2023 suggest cancer and breakthrough therapy approvals should recover from first-half dips and a resumption of inspections in China could revive COVID-delayed products.
Keeping Track: More Rx-To-OTC Switches On Deck After US FDA’s OTC Narcan Approval; Iovance Looks To Bring Cell Therapy To Melanoma
The latest drug development news and highlights form the Pink Sheet’s US FDA Performance Tracker.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Genesis Biopharma
- Lion Biotechnologies, Inc. (LBIO)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice